Long-term trends in drug prescription for hospitalized patients with congestive heart failure. Influence of type of dysfunction;Evolución a largo plazo de la prescripción de fármacos en pacientes hospitalizados por insuficiencia cardíaca congestiva. Influencia del patrón de disfunción

Revista Espanola de Cardiologia

Volumn 58, Issue 4, 2005, Pages 381-388

  Shamagian, Lilian Grigorian ^a   Román, Alfonso Varela ^a   Lamela, Alejandro Virgos ^a   Veloso, Pedro Rigueiro ^a   García Acuña, José M ^a   González Juanatey, José Ramon ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Congestive heart failure; Left ventricular systolic function; Pharmacological management

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; MORTALITY; PRESCRIPTION; PUBLICATION; SYSTOLE;

EID: 19444380302     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13073895     Document Type: Article

References (29)

1. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitors enalapril on the long term progression of left ventricular disfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992;86:431-8.
2. Flather M, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long term ACE-inhibitor therapy in patients with heart failure of left ventricular disfunction: a systematic overview of data from individual patients. ACE-inhibitor myocardial infarction collaborative group. Lancet. 2000;355:1575-81.
3. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-55.
4. CIBIS II. Investigators and Committees. The Cardiac Insufficiency bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353: 2001-7.
6. Pitt B, Zannad F, Remme WJ, Castaigne A, Pérez A, Palensky J, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
7. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-6.
8. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM: overall programme. Lancet. 2003;362:759-66.
9. Digitalis Investigation Group (DIG). The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-33.
10. Remme WJ, Swedberg K. Guidelines for diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-60.
11. Navarro-López F. Guías para el diagnóstico y manejo de la insuficiencia cardíaca y shock cardiogénico. Informe del Grupo de Trabajo de Insuficiencia Cardíaca de la Sociedad Española de Cardiología. Rev Esp Cardiol. 1999;52:1-54.
12. Varela-Román A, Grigorian L, Barge E, Bassante P, Gil de la Peña M, González-Juanatey JR. Heart failure in patients with preserved and deteriorated left ventricular ejection fraction: long term prognosis. Heart. 2005. En prensa.
13. Barrios Alonso V, Pena Pérez G, González-Juanatey JR, Alegría Ezquerra E, Lozano Vidal E, Llisterri Caro JV, et al. Hipertensión arterial e insuficiencia cardíaca en las consultas de atención primaria y de cardiología en España. Rev Clin Esp. 2003;206:334-42.
14. García Castelo A, Muñiz García J, Sesma Sánchez P, Castro Beiras A. Utilización de recursos diagnósticos y terapéuticos en pacientes ingresados por insuficiencia cardíaca: influencia del servicio de ingreso (estudio INCARGAL). Rev Esp Cardiol. 2003;56: 49-56.
15. Muñiz García J, Mosquera Pérez I, Freire Castroseiros E, García Castelo A, Castro-Beiras A. Uso de anticoagulación al alta hospitalaria en pacientes con insuficiencia cardíaca y fibrilación auricular. Rev Esp Cardiol. 2003;56:880-7.
16. Permanyer Miralda G, Soriano N, Brotons C, Moral I, Pinar J, Cascant P, et al. Características basales y determinantes de la evolución en pacientes ingresados por insuficiencia cardíaca en un hospital general. Rev Esp Cardiol. 2002;55:571-8.
17. Ojeda S, Anguita M, Muñoz JF, Rodríguez MT, Mesa D, Franco M, et al. Características clínicas y pronóstico a medio plazo de la insuficiencia cardíaca con función sistólica conservada. ¿Es diferente de la insuficiencia cardíaca sistólica? Rev Esp Cardiol. 2003; 56:1050-6.
18. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-9.
19. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. The study group of diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart J. 2003;24:464-74.
20. Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet. 2002;360:1631-9.
21. González-Juanatey JR, Mazon P, Varela A. Insuficiencia cardíaca con función sistólica conservada (insuficiencia cardíaca diastólica). En: Anguita M, editor, Manual de insuficiencia cardíaca. Madrid: Sociedad Española de Cardiología; 2003. p. 91-110.
22. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331-6.
23. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003; 24:2090-8.
24. Bouvy ML, Heerdink ER, Leufkens HGM, Hoes AW. Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. Eur J Heart Fail. 2003;5:195-200.
25. Grupo de Trabajo de Insuficiencia Cardíaca de la Sociedad Española de Medicina Interna (SEMI). La insuficiencia cardíaca en los servicios de medicina interna (estudio SEMI-IC). Med Clin (Barc). 2002;118:605-10.
26. González-Juanatey JR, Mazón Ramos P. Bloqueo aldosterónico en la insuficiencia cardíaca. Tanto por tan poco. Med Clin (Barc). 2002;118:779-81.
27. Lenzen MJ, Scholte op Reimer WJM, Boersma E, Vantrimpont PJMJ, Follath F, Swedberg K, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J. 2004;25:1214-20.
28. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-92.
29. Mohindra SK, Udeani GO. Long acting verapamil and heart failure. JAMA. 1989;261:994.